• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

RANK-L 抑制剂治疗难治性广泛颅面骨纤维结构不良:一例报告。

RANK-L inhibitor as a promising agent for refractory extensive craniofacial fibrous dysplasia: A case report.

机构信息

Department of Otolaryngology - Head and Neck Surgery, Tanta University, Tanta, Egypt.

Department of Otolaryngology - Head and Neck Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

出版信息

Head Neck. 2024 Jan;46(1):E1-E5. doi: 10.1002/hed.27546. Epub 2023 Oct 12.

DOI:10.1002/hed.27546
PMID:37823398
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10843282/
Abstract

BACKGROUND

McCune-Albright syndrome is a rare disorder characterized by polyostotic fibrous dysplasia (FD), café-au-lait skin pigmentation, and endocrine dysfunction. Extensive FD in the craniofacial region can present significant challenges in terms of disease control and carries a high risk of permanent visual impairment.

METHODS

We present a case of medically and surgically resistant FD that required nine optic nerve decompressions.

RESULTS

The condition was ultimately controlled with the use of the denosumab agent.

CONCLUSION

The case highlights the importance and potential efficacy of denosumab in resistant FD management, particularly in cases involving sensitive organs.

摘要

背景

McCune-Albright 综合征是一种罕见疾病,其特征为多骨性纤维结构不良(FD)、咖啡牛奶斑皮肤色素沉着和内分泌功能障碍。颅面区域广泛的 FD 在疾病控制方面会带来重大挑战,并存在永久性视力损害的高风险。

方法

我们报告了一例经药物和手术治疗抵抗的 FD,该患者需要进行九次视神经减压手术。

结果

最终使用地舒单抗药物控制了病情。

结论

该病例突出了地舒单抗在抵抗性 FD 管理中的重要性和潜在疗效,特别是在涉及敏感器官的情况下。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab01/10843282/ca9e3502b8b0/nihms-1936263-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab01/10843282/497b2f8f1c35/nihms-1936263-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab01/10843282/3e008ad1c79c/nihms-1936263-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab01/10843282/ba0d07a98e18/nihms-1936263-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab01/10843282/81669eaa49c5/nihms-1936263-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab01/10843282/ca9e3502b8b0/nihms-1936263-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab01/10843282/497b2f8f1c35/nihms-1936263-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab01/10843282/3e008ad1c79c/nihms-1936263-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab01/10843282/ba0d07a98e18/nihms-1936263-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab01/10843282/81669eaa49c5/nihms-1936263-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab01/10843282/ca9e3502b8b0/nihms-1936263-f0005.jpg

相似文献

1
RANK-L inhibitor as a promising agent for refractory extensive craniofacial fibrous dysplasia: A case report.RANK-L 抑制剂治疗难治性广泛颅面骨纤维结构不良:一例报告。
Head Neck. 2024 Jan;46(1):E1-E5. doi: 10.1002/hed.27546. Epub 2023 Oct 12.
2
Craniofacial fibrous dysplasia associated with McCune-Albright syndrome: challenges in diagnosis and treatment: case reports.颅面纤维结构不良伴 McCune-Albright 综合征:诊断和治疗的挑战:病例报告。
BMC Oral Health. 2019 Aug 8;19(1):180. doi: 10.1186/s12903-019-0872-8.
3
McCune-Albright syndrome with craniofacial dysplasia: Clinical review and surgical management.伴有颅面发育异常的McCune-Albright综合征:临床综述与外科治疗
Surg Neurol Int. 2016 Mar 11;7(Suppl 6):S165-9. doi: 10.4103/2152-7806.178567. eCollection 2016.
4
Craniofacial Fibrous Dysplasia Involvements of Mccune-Albright Syndrome: A Review with an Additional Case.《McCune-Albright 综合征相关颅面纤维结构不良:综述及附加病例》
Curr Med Imaging. 2021;17(7):864-870. doi: 10.2174/1573405616666201209102418.
5
A case of atypical McCune-Albright syndrome requiring optic nerve decompression.一例需要视神经减压的非典型麦库恩-奥尔布赖特综合征病例。
Ann Plast Surg. 1999 Oct;43(4):430-5. doi: 10.1097/00000637-199910000-00015.
6
Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients With Fibrous Dysplasia/McCune-Albright Syndrome.地舒单抗可降低纤维结构不良/ McCune-Albright 综合征患者病灶氟骨放射性核素摄取 PET-CT 中的氟骨放射性核素摄取。
J Clin Endocrinol Metab. 2021 Jul 13;106(8):e2980-e2994. doi: 10.1210/clinem/dgab212.
7
Dental perspectives in fibrous dysplasia and McCune-Albright syndrome.纤维结构不良和 McCune-Albright 综合征的口腔视角。
Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Sep;116(3):e149-55. doi: 10.1016/j.oooo.2013.05.023.
8
McCune-Albright Syndrome: A Case From Mauritius.麦库恩-奥尔布赖特综合征:毛里求斯的一个病例。
Cureus. 2024 Nov 1;16(11):e72810. doi: 10.7759/cureus.72810. eCollection 2024 Nov.
9
Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune-Albright Syndrome.靶向纤维性骨发育不良/ McCune-Albright 综合征疼痛的药物干预。
Int J Mol Sci. 2023 Jan 29;24(3):2550. doi: 10.3390/ijms24032550.
10
Polyostotic Fibrous Dysplasia With and Without McCune-Albright Syndrome-Clinical Features in a Nordic Pediatric Cohort.伴有或不伴有McCune-Albright综合征的多骨型纤维发育不良——北欧儿科队列中的临床特征
Front Endocrinol (Lausanne). 2018 Mar 15;9:96. doi: 10.3389/fendo.2018.00096. eCollection 2018.

引用本文的文献

1
Rebound Hypercalcemia After Denosumab Cessation in Adult Fibrous Dysplasia: A Case Report and Clinical Alert.成人骨纤维发育不良停用地诺单抗后出现反弹性高钙血症:一例报告及临床警示
Case Rep Endocrinol. 2025 Sep 4;2025:4553039. doi: 10.1155/crie/4553039. eCollection 2025.

本文引用的文献

1
Safety and Efficacy of Denosumab for Fibrous Dysplasia of Bone.地诺单抗治疗骨纤维发育不良的安全性和有效性。
N Engl J Med. 2023 Feb 23;388(8):766-768. doi: 10.1056/NEJMc2214862.
2
Age-Related Changes and Effects of Bisphosphonates on Bone Turnover and Disease Progression in Fibrous Dysplasia of Bone.骨纤维异常增殖症中骨转换和疾病进展的年龄相关变化及双膦酸盐的作用
J Bone Miner Res. 2019 Apr;34(4):653-660. doi: 10.1002/jbmr.3649. Epub 2019 Jan 15.
3
A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone.一项阿伦膦酸盐治疗骨纤维结构不良的随机、双盲、安慰剂对照试验。
J Clin Endocrinol Metab. 2014 Nov;99(11):4133-40. doi: 10.1210/jc.2014-1371. Epub 2014 Jul 17.
4
Clinical guidelines for the management of craniofacial fibrous dysplasia.颅面纤维结构不良管理的临床指南。
Orphanet J Rare Dis. 2012 May 24;7 Suppl 1(Suppl 1):S2. doi: 10.1186/1750-1172-7-S1-S2.
5
Fibrous dysplasia. Pathophysiology, evaluation, and treatment.骨纤维异常增殖症。病理生理学、评估与治疗。
J Bone Joint Surg Am. 2005 Aug;87(8):1848-64. doi: 10.2106/JBJS.D.02942.